FindTrial
Sign In

LAG525

DRUG6 trials

Sponsors

Novartis Pharma AG, Novartis Pharmaceuticals

Conditions

Advanced Solid TumorsAdvanced Well-differentiated Neuroendocrine TumorsCastration Resistant Prostate AdenocarcinomaDifferent types of advanced cancerDiffuse Large B Cell LymphomaEsophageal AdenocarcinomaGastric AdenocarcinomaMelanoma

Phase 1

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
CompletedNCT02460224
Novartis PharmaceuticalsAdvanced Solid Tumors
Start: 2015-06-17End: 2020-12-31Updated: 2022-02-10
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
TerminatedNCT03742349
Novartis PharmaceuticalsTriple Negative Breast Cancer (TNBC)
Start: 2019-01-31End: 2023-02-06Updated: 2025-05-18
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments
Active, not recruitingCTIS2023-508841-42-00
Novartis Pharma AGDifferent types of advanced cancer
Start: 2019-10-30Target: 75Updated: 2025-10-28

Phase 2

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
CompletedNCT03365791
Novartis PharmaceuticalsAdvanced Well-differentiated Neuroendocrine Tumors, Castration Resistant Prostate Adenocarcinoma, Diffuse Large B Cell Lymphoma +5
Start: 2018-01-24End: 2020-09-17Updated: 2022-05-27
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
CompletedNCT03484923
Novartis PharmaceuticalsMelanoma
Start: 2018-09-10End: 2022-12-30Updated: 2024-06-18
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
CompletedNCT03499899
Novartis PharmaceuticalsTriple-negative Breast Cancer
Start: 2018-07-02End: 2021-11-24Updated: 2023-01-30

Related Papers

Immunological characterization of a long-lasting response in a patient with metastatic triple-negative breast cancer treated with PD-1 and LAG-3 blockade.
2024-02-0910 citations
Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
2023-08-075 citations
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
Journal for ImmunoTherapy of Cancer2022-02-01145 citations
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
European Journal of Cancer2021-09-2724 citations
387 A Phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
Regular and Young Investigator Award Abstracts2020-11-0111 citations
Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)
Cancer Research2019-07-011 citations
Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM)
Clinical Trials2019-07-011 citations
Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
Journal of Clinical Oncology2019-05-2059 citations
A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM)
Annals of Oncology2018-10-016 citations
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
Journal of Clinical Oncology2018-05-2069 citations
A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies.
Journal of Clinical Oncology2018-05-205 citations